Company intelligence / Profile preview

Knopp Biosciences

Pittsburgh, Pennsylvania, United Statesknoppbio.com ↗

Ownership: Private
Employees: ~26
Development stage: Phase 3

Overview

Dexpramipexole showed promising Phase II results slowing ALS progression but failed Phase III trial under Biogen. Ongoing development of dexpramipexole for eosinophilic asthma via Areteia Therapeutics.

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

dexpramipexole

Phase 3

Indications: Eosinophilic asthma, Hypereosinophilic syndrome

1 more asset in the full pipeline.

Request access →

Partnerships

Licensing deal with Biogen Inc. for dexpramipexole until 2014.Partnership with Population Health Partners and Bain Capital Life Sciences leading to creation of Areteia Therapeutics which now develops the Dex pipeline.Sale of Kv7 platform assets to Biohaven Pharmaceuticals Limited.

Beyond the preview

Go deeper on Knopp Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Knopp Biosciences.

Explore the full profile